| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910972764303321 |
|
|
Titolo |
Handbook of drugs for tropical parasitic infections / / Yakoub Aden Abdi. [et al.] |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
London ; ; Bristol, PA, : Taylor & Francis, c2003 |
|
London ; ; Bristol, Pa. : , : Taylor & Francis, , 1995 |
|
|
|
|
|
|
|
|
|
ISBN |
|
0-429-17889-1 |
1-4822-7253-9 |
9786610195640 |
1-280-19564-9 |
0-585-46045-0 |
0-203-21151-0 |
|
|
|
|
|
|
|
|
Edizione |
[2nd ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (192 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Antiparasitic agents |
Antiprotozoal Agents - therapeutic use |
Parasitic Diseases - drug therapy |
Tropical Medicine |
Handbook |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Previous ed. cataloged under author Gustafsson. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Book Cover; Title; Contents; Preface; Acknowledgement; Abbreviations; Introduction; Drug recommendations; Albendazole; Amphotericin B; Antimony compounds; Artemisinin and derivatives; Bephenium hydroxynaphthoate; Bithionol; Chloroquine; Dehydroemetine; Diethylcarbamazine; Diloxanide; Eflornithine; Halofantrine; Ivermectin; Levamisole; Mebendazole; Mefloquine; Melarsoprol; Metrifonate; Metronidazole; Niclosamide; Nifurtimox; Oxamniquine; Pentamidine; Piperazine; Praziquantel; Primaquine; Proguanil; Pyrantel; Pyrimethamine; Pyrvinium pamoate; Quinine; Sulphadoxine; Suramin; Tetracyclines |
ThiabendazoleTinidazole; Index |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Parasitic infections such as malaria, schistosomiasis, trypanosomiasis |
|
|
|
|
|
|
|
|
|
|
and onchoceriasis are the scourge of the tropical countries. Many of the drugs used for the treatment of tropical parasitic infections were introduced more than 30 years ago. Most of these drugs are toxic and have complicated dosage regimens, but, because of the low economic incentive, pharmaceutical companies have shown little interest in developing new drugs to control diseases prevalent in developing countries.; However, there has been notable progress in research into parasitic diseases and a number of important drugs h |
|
|
|
|
|
| |